Clinical Trial Update: A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study is evaluating SDX-7320 with Eribulin for breast cancer, including metastatic triple-negative breast cancer. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• SDX-7320

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING